MEGAN CHAVEZ: Open Payments
NPI 1386265783 · MCALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,227 in 315 payments from 16 companies in 2025. Trend: 2023 $4,381 · 2024 $5,542 · 2025 $5,227
Food & beverage: $5,227
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 57 | $779 |
| Teva Pharmaceuticals USA, Inc. | 50 | $700 |
| ABBVIE INC. | 57 | $653 |
| Alkermes, Inc. | 28 | $602 |
| E.R. Squibb & Sons, L.L.C. | 21 | $574 |
| Neurocrine BioSciences, Inc. | 12 | $512 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 40 | $472 |
| Lundbeck LLC | 10 | $300 |
| Axsome Therapeutics, Inc. | 11 | $171 |
| Supernus Pharmaceuticals, Inc. | 12 | $146 |
Products named: REXULTI, VRAYLAR, INGREZZA, CAPLYTA, COBENFY, AUSTEDO XR, ARISTADA, UZEDY.
Industry payments across TX — which companies pay providers there.
